

Resource Summary Report

Generated by [NIF](#) on Aug 18, 2026

OptiType

RRID:SCR_022279

Type: Tool

Proper Citation

OptiType (RRID:SCR_022279)

Resource Information

URL: <https://github.com/FRED-2/OptiType>

Proper Citation: OptiType (RRID:SCR_022279)

Description: Software tool for precision HLA typing from next generation sequencing data.

Resource Type: data processing software, software resource, data analysis software, software application

Defining Citation: [PMID:25143287](#)

Keywords: Precision HLA typing, next generation sequencing data, HLA typing, NGS data

Funding: German Research Foundation ;
German Federal Ministry of Education and Research

Availability: Free, Available for download, Freely available

Resource Name: OptiType

Resource ID: SCR_022279

Alternate IDs: OMICS_05461

Alternate URLs: <https://sources.debian.org/src/optitype/>

Record Creation Time: 20220512T050141+0000

Record Last Update: 20260818T043702+0000

Ratings and Alerts

No rating or validation information has been found for OptiType.

No alerts have been found for OptiType.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 50 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

De Marco L, et al. (2026) NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome. *Molecular cancer therapeutics*, 25(4), 650.

Romeyer-Dherbey JH, et al. (2026) Ancient DNA study provides clues to leprosy susceptibility in medieval Europe. *Genome biology*, 27(1), 4.

Tomás L, et al. (2026) Cancer evolution and multi-omic profile of relapsed colorectal liver metastases after treatment. *Genome medicine*, 18(1).

Mehta S, et al. (2026) iPepGen: a modular, immunopeptidogenomic analysis pipeline for discovery, verification, and prioritization of cancer peptide neoantigen candidates. *Genome biology*, 27(1).

Apavaloaei A, et al. (2025) Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer. *Nature cancer*, 6(8), 1419.

Mendiola-Soto DK, et al. (2025) Somatic Mutations in DNA Mismatch Repair Genes, Mutation Rate and Neoantigen Load in Acute Lymphoblastic Leukemia. *Pharmaceuticals (Basel, Switzerland)*, 18(9).

Yudina A, et al. (2025) Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort. *Communications medicine*, 5(1), 236.

Stupichev D, et al. (2025) AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma. *Cell reports. Medicine*, 6(8), 102299.

Obispo D, et al. (2024) New Associations with the HIV Predisposing and Protective Alleles of the Human Leukocyte Antigen System in a Peruvian Population. *Viruses*, 16(11).

Skadborg SK, et al. (2024) Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways. *Cancer immunology research*, 12(9), 1202.

Ricker CA, et al. (2024) Historical perspective and future directions: computational science in immuno-oncology. *Journal for immunotherapy of cancer*, 12(1).

Lai SK, et al. (2024) A novel framework for human leukocyte antigen (HLA) genotyping using probe capture-based targeted next-generation sequencing and computational analysis. *Computational and structural biotechnology journal*, 23, 1562.

Das A, et al. (2024) Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium. *Cancer discovery*, 14(2), 258.

Barquera R, et al. (2024) Ancient genomes reveal insights into ritual life at Chichén Itzá. *Nature*, 630(8018), 912.

Bulashevskaya A, et al. (2024) Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy. *Frontiers in immunology*, 15, 1394003.

Zhang C, et al. (2024) Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). *Cell reports. Medicine*, 5(7), 101615.

Burleigh A, et al. (2024) Genetic testing of Behçet's disease using next-generation sequencing to identify monogenic mimics and HLA-B*51. *Rheumatology (Oxford, England)*, 63(12), 3457.

Deng Y, et al. (2024) Multicellular ecotypes shape progression of lung adenocarcinoma from ground-glass opacity toward advanced stages. *Cell reports. Medicine*, 5(4), 101489.

Sverchkova A, et al. (2024) Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response. *BMC medical genomics*, 17(1), 37.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. *Cancer cell*, 42(1), 135.